BIOGEN INC/ US09062X1037 /
2024-05-16 2:31:19 PM | Chg. +0.20 | Volume | Bid4:13:36 PM | Ask4:13:36 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
215.50EUR | +0.09% | 42 Turnover: 9,051 |
211.30Bid Size: 84 | 212.90Ask Size: 135 | 30.86 bill.EUR | - | - |
GlobeNewswire
1:30 PM
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
05-15
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Su...
GlobeNewswire
05-09
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
05-08
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
05-07
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
GlobeNewswire
04-29
Muscular Dystrophy Association Launches ALS Awareness Month with Public Service Announcement ‘Answer...
GlobeNewswire
04-25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
03-13
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer